MDimune’s BioDrone platform
The MDimune BioDrone platform [Image courtesy of MDimune]
BioDrone is a novel drug delivery technology based on cell-derived vesicles
Category: Health, Medical and Biotech
Subcategory: Advanced Drug Delivery
From the winners: “BioDrone is a next-generation drug delivery platform that relies on cell-derived vesicles obtained from MDimune’s proprietary extrusion technology that converts virtually any human cells into nanovesicles. BioDrone is safe and highly effective in the targeted delivery of various drugs, thereby reducing side effects and maximizing efficacy.”
“The BioDrone platform is an innovative drug delivery technology that relies on cell-derived vesicles produced from human cells by using extrusion technology. It all began with a team of scientists exploring methods for obtaining exosomes or similar nanovesicles, which are limited in productivity and thus less suitable for clinical applications, in a large quantity. MDimune then acquired this potentially powerful extrusion technology and developed into a commercial scale to overcome the challenges of existing drug carriers, such as safety concerns of synthetic lipids and viruses, or low productivity and increasing cost of goods for exosomes.”
“MDimune’s BioDrone technology addresses the most critical limitations of the current drug delivery platforms, such as a wide range of side effects and limited targeting abilities. Compared to similar classes of nanovesicles like exosomes, BioDrone enables up to 100x greater yield in vesicle production that is more suitable for clinical applications. Derived from natural human cells, cell-derived vesicles produced by extrusion technology display little toxicity or immunogenicity while exhibiting a high level of flexibility to allow various surface engineering, which can be used to steer vesicles toward lesions in a more selective manner.”
Next>>